Welcome to Seeking Alpha’s Venture Capital Deals of the Week. Follow this account and turn on the e-mail alert to receive VCDeals in your inbox on Friday afternoons.
AbbVie Ventures (ABBV) participated in the $50M Series A for Quench Bio, a company leveraging gasdermin biology and innate immunology to develop medicines for severe inflammatory disease. RA Capital led the round, and Quench co-founders Atlas Venture and Arix Bioscience participated.
Quench Bio's lead therapeutic approach involves inhibiting Gasdermin D, a key target at the core of multiple inflammatory cell death pathways, including pyroptosis and NETosis. When